Dallas, TX -- (SBWire) -- 10/30/2010 -- ReportsandReports announce Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis Market Research Report in its Store.
Browse complete Report at: Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis
http://www.reportsandreports.com/reports/36530-musculoskeletal-disorders-therapeutics-to-2016-introduction-of-.html
Report Summary
GBI Research’s report, “Musculoskeletal Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First-in-class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis", provides in-depth analysis of unmet needs, drivers and barriers that impact the global musculoskeletal disorders market. The report analyzes the markets for musculoskeletal disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan.
Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
Scope
The scope of this report includes:
Annualized market data for the musculoskeletal disorders therapeutics market from 2001 to 2009, with forecasts to 2016.
Data and analysis on the musculoskeletal disorders therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
Market Data on geographical landscape and therapeutic landscape including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
Key drivers and restraints that have created significant impact on the market.
Competitive landscape of the global musculoskeletal disorders therapeutics market including top companies benchmarking. The key companies studied in this report are Roche/Genentech, Novartis, Amgen, Merck/Schering-Plough, Pfizer/Wyeth, Bristol-Myers Squibb and Eli Lilly, Procter and Gamble, Johnson and Johnson, Abbott Laboratories and Boehringer Ingelheim
Key M&A activities, Licensing Agreements, that have taken place between 2008 and 2009 in the musculoskeletal disorders therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
Build effective strategies to launch their pipeline products by identifying potential geographies.
Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
Develop key strategic initiatives by studying the key strategies of top competitors.
Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.
Browse all GBI Research Market Research Reports
http://www.reportsandreports.com/publisher/gbi-research-market-research.html
Browse all Pharmaceuticals Market Research Reports
http://www.reportsandreports.com/cat/pharmaceuticals-market-research.html
Browse all Newly Published Market Research Reports http://www.reportsandreports.com/LatestReport.aspx
Original Source: Monoclonal Antibodies Market
Buy Now: Research
Related Reports:
The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities
http://www.reportsandreports.com/reports/18569-the-future-of-blood-disorders-therapeutics-analysis-and-market-f.html
Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
http://www.reportsandreports.com/reports/33055-manufacturing-of-biologics-increasing-demand-for-monoclonal-ant.html
Monoclonal antibodies: 2009 update
http://www.reportsandreports.com/reports/7621-monoclonal-antibodies-2009-update.html
Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging technologies and new therapeutic candidates
http://www.reportsandreports.com/reports/18265-preclinical-development-of-monoclonal-antibodies-and-related-biol.html
The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
http://www.reportsandreports.com/reports/18452-the-future-of-monoclonal-antibodies-market-forecasts-to-2015-c.html
About Reports and Reports
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies With First - in - Class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis Now Available at Reportsandreports